Rémi Letestu

4PUBLICATIONS
29CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 20, 2026
Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia-Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups.

|Apr 07, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier

|Nov 29, 2021
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.

Cristina Bagacean, Rémi Letestu, Chadi Al-Nawakil

|Sep 16, 2020
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.

Rémi Letestu, Abdelmalek Dahmani, Marouane Boubaya

Pageof 1

Frequent Collaborators

3 joint publications

Bernard Drénou

2 joint publications

Alain Delmer

2 joint publications

Marie C Béné

2 joint publications

Cécile Tomowiak